Absence of rapidly developing resistance during treatment of cystic fibrosis patients with aztreonam.
The in vitro activity of aztreonam and 10 other antibiotics was determined for clinical isolates of Pseudomonas aeruginosa from 18 cystic fibrosis patients obtained before, at the end of, and 7-14 days after the completion of therapy with aztreonam. The percent of isolates susceptible to aztreonam at each sampling period were 79%, 78%, and 81% respectively.
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D001398:Aztreonam / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications*; D004352:Drug Resistance, Microbial; D006801:Humans; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology
D000900:Anti-Bacterial Agents; D001398:Aztreonam